A study conducted by German researchers shows an AstraZeneca’s dose and Pfizer/BioNTech’s COVID-19 dose combination are immunologically exceptional. The study shows that the vaccine mix ,having the first dose of AstraZeneca incorporated with the second dose of Pfizer/BioNTech, produces significantly higher anti-spike titers and more neutralizing activity against the rising variants.
The findings suggest vaccine mix doses could be sufficient to strengthen the immune system against different variants of concern.
German Health Minister, Jens Spahn announced standards to boost the potency of the country’s vaccination program against an expected wave of the Delta variant of COVID-19.
He said that the addition of the mRNA shot along with AstraZeneca will provide additional immunity against the Delta variant, which is epidemic in Britain and is foreseen to become so in Germany this month.
Having the Pfizer/BioNTech vaccine as the second dose considerably increased anti-S IgG antibody levels by 11.5-fold compared to a 2.9-fold increase observed in people who received both AstraZeneca vaccines. Identical rises in anti-S IgA antibody levels were also observed, indicating a better humoral immune reaction with mixed-match doses.
Although, the jab has been related to rare instances of a blood-clotting condition known as thrombosis with thrombocytopaenia.
The vaccines developed by Pfizer and Moderna are based on the same novel messenger RNA technology, which trains the body to reproduce spike proteins, analogous to that found on the coronavirus. When exposed to the real virus later, the body recognises the spike proteins and can combat them off.
Several countries, including Canada, Spain, and South Korea, have already approved vaccine dose mixing. The health authorities of Germany proposed the mix “regardless of age” and with the least gap of four weeks between the two shots.
Across Europe, the number of new cases surged again last week after 10 weeks of drop, according to the World Health Organization.